On October 26, 2021 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, which addresses a fundamental biologic mechanism of immune suppression in cancer, reported that it will host a conference call on Tuesday, November 2nd 2021, at 4:30pm ET to report its financial results for the third quarter of 2021 (Press release, Infinity Pharmaceuticals, OCT 26, 2021, View Source [SID1234591940]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference call & Webcast Details
Date: Tuesday, November 2
Time: 4:30 pm Eastern Time
Webcast: View Source
Toll Free: (877) 316-5293
International: (613) 291-4526
ID Number: 2938945

A live webcast of the conference call can be accessed in the Investors/ Media section of Infinity’s website at www.infi.com and will be available on Infinity’s website for 30 days following the event.